Neurogastrx

5 articles about Neurogastrx

• 

  Money on the Move: August 25 – 31

  9/1/2021

  The hot days of summer are nearing a close, but these life science companies aren’t cooling off their fundraising efforts. Here’s a brief overview of who’s heating up their coffers this week.

• Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders

  8/26/2021

  Neurogastrx, Inc., a privately held specialty pharmaceutical company developing transformative therapies for gastrointestinal disorders, announced the successful completion of a $60 million Series B crossover round led by Vivo Capital.

• Neurogastrx Announces Agreement with Daewoong Pharmaceutical to Develop Fexuprazan for Treatment of Acid-Related GI Disorders in the U.S.

  6/8/2021

  Neurogastrx, Inc., announced today that it has entered into an exclusive license agreement with Daewoong Pharmaceutical Co., Ltd., of Seoul, South Korea, for the development and commercialization of fexuprazan, an investigational novel potassium-competitive acid blocker (P-CAB) for the treatment of erosive esophagitis (EE) and other acid-related conditions.

• 

  BioSpace Movers and Shakers - Oct. 22

  10/22/2018

  Execs at Novo Nordisk, AbbVie, and more made moves this week. Here's a roundup of those changes.
• 

  Neurogastrx Bags $45M, a New CEO and a HQ Move to the Greater Boston Area

  1/4/2018

  The Series A financing was co-led by 5AM Ventures, OrbiMed Advisors and venBio Partners.